Open trial of the interferon therapy for withdrawal of entecavir for patient with chronic hepatitis B

Open trial of the interferon therapy for withdrawal of entecavir for patient with chronic hepatitis B - Open trial of the interferon therapy for withdrawal of entecavir for patient with chronic hepatitis B

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004906

Enrollment

Registered

2011-01-19

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

6 months of interferon or 6-12 months of peg-interferon treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with chronic hepatitis B treated with entecavir for more than 6 months. Just before the trial, HBV DNA less than 2.1 log copies/mL, HBs antigen positive, HBe antigen negative, ALT 30 IU/L or less, platelet count 150,000/&#181;L or more Non-cirrhosis Without hepatocellular carcinoma

Exclusion criteria

Exclusion criteria: 1,allergy with entecavir, interferon or vaccination 2,interferon treatment before 6 months of the trial 3,pregnancy or lactation period 4,severe heart disease, chronic renal failure, depression, severe psychotic disease, liver cirrhosis, brain hemorrhage or infarction, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, HCV infection, autoimmune disease 5,treated with shosaiko-to

Design outcomes

Primary

Measure	Time frame
maintenance of ALT	—

Secondary

Measure	Time frame
HBe antigen, anti-HBe HBV DNA less than 4 log copies/mL	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026